P21

Developed by Khalid Iqbal's lab at the New York State Institute for Basic Research in Developmental Disabilities (IBR). Synthesised by epitope mapping of Cerebrolysin's active neurogenic fraction, tracing activity to CNTF residues 148–151 (DGGL). The first publication describing P021's neurogenic enhancement in normal mice appeared in FEBS Letters in 2010 (Li et al., PMID 20600002). Subsequent preclinical development added N-acetylation and C-terminal adamantane to yield the final Ac-DGGLAG-NH2 structure, improving plasma half-life from <30 min (unmodified CNTF) to >3 hours and enabling oral delivery. Phanes Biotech (Pennsylvania) holds the IND-application pipeline as of 2025.

Dual primary mechanism: (1) Competitive inhibition of leukemia inhibitory factor (LIF) signalling — LIF normally suppresses neural progenitor proliferation via the JAK-STAT3 axis; P21 blocks this brake and disinhibits hippocampal neurogenesis in the dentate gyrus subgranular zone. (2) Upregulation of BDNF expression via activated downstream cascades (PLC/PKC, MEK/ERK, PI3K/Akt, CREB phosphorylation), leading to TrkB-mediated synaptogenesis and inhibition of glycogen synthase kinase-3β (GSK-3β, the major tau kinase). GSK-3β inhibition via Akt-mediated Ser9 phosphorylation reduces aberrant tau hyperphosphorylation at multiple AD-relevant epitopes. Secondary effects include normalisation of glutamate receptor subunits (NMDAR), restoration of MAP2 and synaptophysin, and partial reduction of soluble Aβ via neurogenesis-linked APP processing. The adamantane moiety provides steric protection against exopeptidase degradation and raises lipid solubility for BBB transit (MW 578.3 Da, below 600 Da BBB exclusion threshold).

Baazaoui & Iqbal (Alzheimer's Research & Therapy, 2017, PMID 28655344): 3xTg-AD female mice, P021 diet 162 nmol/day from 3 months to 21 months. Rescued dendritic and synaptic deficits, boosted neurogenesis, reversed cognitive impairment at 9, 15, and 18 month checkpoints; no adverse events in 18-month chronic study. Wei et al. (Journal of Alzheimer's Disease, 2021, PMID 34057082): postnatal P021 treatment in 3xTg-AD mice preserved spatial and short-term memory at 4 months; increased pCREB, BDNF, PLC/PKC, MEK/ERK, PI3K/Akt; normalised NMDAR; no motor deficits over 120-day course. Li et al. (FEBS Letters, 2010, PMID 20600002): P21 enhanced spatial reference and short-term memory in normal C57Bl/6 mice; induced neurogenesis in dentate gyrus granular cell layer. Kazim & Iqbal review (Molecular Neurodegeneration, 2016, PMID 27400746): summarised preclinical evidence — reduced tau hyperphosphorylation, improved synaptic markers MAP2 and synaptophysin, reduced soluble Aβ, oral pharmacokinetics plasma t½ >3 h, >95% stable in artificial intestinal fluid at 2 h, >90% stable in artificial gastric juice at 30 min. Baazaoui & Iqbal (Biomolecules, 2022, PMID 36291618): review confirming P021 as a disease-modifying candidate overcoming full-length CNTF limitations (BBB impermeability, t½ 2.9 min, severe adverse effects). Falangola et al. (Magnetic Resonance Imaging, 2026, PMID 41740658): chronic oral P021 from 2.5 to 8 months in 3xTg-AD mice produced measurable white-matter microstructure improvements (increased fractional anisotropy in corpus callosum) and partial normalisation of diffusion metrics; no undesirable side effects. Mottolese et al. (Journal of Neurodevelopmental Disorders, 2024, DOI 10.1186/s11689-024-09583-4): P021 rescued neuronal proliferation and maturation in CDKL5-deficient human neuroblastoma cells in vitro but failed to improve behavioural or neuroanatomical outcomes in CDKL5 knockout mice — demonstrating disease-context dependency. All evidence is preclinical; zero human clinical trials registered or completed as of 2026-05-04.